AbbVie Inc. (ABBV)
AbbVie is a biopharmaceutical company known for immunology drugs, aesthetics, and neuroscience treatments. It has worked to replace revenue from its Humira franchise with newer immunology therapies.
Health Care stock comparison
ABBV vs DHR: which business are you actually underwriting?
Compare AbbVie Inc. with Danaher Corporation using their business models, SEC classifications, fiscal calendars, current primary filings, and the research questions that matter. This is a thesis framework—not a price target or automatic winner.
- Sector
- Health
- Industry
- Different SIC
- Shared themes
- 1
- Updated
- 2026-02-24
ABBV vs DHR: quick comparison
| Company fact | ABBV | DHR |
|---|---|---|
| Company | AbbVie Inc. | Danaher Corporation |
| Exchange | NYSE | NYSE |
| Headquarters | North Chicago, Illinois | Washington, District of Columbia |
| Founded | 2013 | 1969 |
| SEC industry | Pharmaceutical Preparations | Industrial Instruments For Measurement, Display, and Control |
| Fiscal year-end | December 31 | December 31 |
| Latest annual filing | 10-K · 2026-02-20 | 10-K · 2026-02-24 |
How the businesses differ
Danaher Corporation (DHR)
Danaher is a science and technology conglomerate focused on life sciences, diagnostics, and biotechnology after divesting its industrial businesses. Its recurring consumables and reagents generate steady demand.
The useful starting point is not which ticker has performed better. It is whether the two companies convert the same economic forces into revenue and cash flow in the same way. ABBV is classified by the SEC as Pharmaceutical Preparations, while DHR is classified as Industrial Instruments For Measurement, Display, and Control. The different industry codes are a warning against treating sector membership as proof of identical economics.
Which thesis does each company fit?
Use the distinction below to decide which filing deserves deeper work. It is a research routing rule, not a recommendation or prediction.
Study ABBV when…
- Drug approvals and clinical-trial readouts
- Medicare and drug-pricing policy
- Demographics and an aging population
- GLP-1 and obesity-drug demand
Study DHR when…
- Drug approvals and clinical-trial readouts
- Medicare and drug-pricing policy
- Demographics and an aging population
- GLP-1 and obesity-drug demand
Shared research themes
US markets
SEC filing comparison and disclosure evidence
Start with primary filings because fiscal calendars and accounting presentation can make superficially similar quarters incomparable.ABBV's fiscal year ends December 31, while DHR's ends December 31. Normalize the reporting periods before comparing growth, margins, capital intensity, or guidance.
The current verified House Clerk snapshot contains 1matched transaction row for ABBVand 0 for DHR. These delayed, range-based disclosures can identify a filing to inspect; they do not establish motive, conviction, or a real-time trading signal.
ABBV primary filings
DHR primary filings
What this comparison cannot tell you
This page does not contain licensed live prices, a valuation model, earnings estimates, portfolio constraints, or a forecast of future returns. SEC classifications can be broad, company descriptions can lag strategic change, and the latest annual filing may predate a material acquisition or divestiture. Read subsequent quarterly and current reports before making a decision.
A stronger business is not automatically the better stock. Starting valuation, expectations, capital structure, cyclicality, dilution, and the probability of each thesis determine the investment outcome. Use this comparison to frame the work, then verify the numbers in the linked filings and current company disclosures.
More comparisons involving ABBV or DHR
ABBV vs DHR FAQs
Are ABBV and DHR direct competitors?
AbbVie Inc. and Danaher Corporation sit in the same Health Care sector but have different SEC industry classifications. The comparison is most useful for portfolio role and sector exposure, not as a claim that every product competes directly.
Which is better, ABBV or DHR?
There is no context-free winner. Compare the operating exposures, filing evidence, valuation, balance sheet, and risks against the specific thesis you are testing. This page deliberately does not turn a static profile into a buy or sell recommendation.
Does this ABBV vs DHR comparison include live prices?
No. Yield Theory does not republish unlicensed real-time market data. Use a regulated broker or licensed quote provider for current prices, then use the primary filings here to test the business thesis.
Where does the company information come from?
Company classifications, fiscal year-ends, and filing links come from the SEC EDGAR submissions API snapshot refreshed 2026-08-10. Business summaries and research themes are maintained by Yield Theory.
Data snapshot: SEC EDGAR submissions API, refreshed 2026-08-10. Independent educational research; not investment advice.
Go beyond ABBV vs DHR.
Yield Theory connects filings, capital flows, catalysts, and risks into an investable research process.
$15/mo or $150/yr · cancel future renewals anytime · sources included